Matthew D Shin
Overview
Explore the profile of Matthew D Shin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin M, Jung E, Moreno-Gonzalez M, Ortega-Rivera O, Steinmetz N
Bioeng Transl Med
. 2024 Jan;
9(1):e10574.
PMID: 38193118
Our lab demonstrated that intratumoral Cowpea mosaic virus (CPMV) is a potent antitumor immunotherapy when used as in situ vaccine. As we pave the way for human clinical translation, formulation...
2.
de Oliveira J, Zhao Z, Xiang Y, Shin M, Villasenor K, Deng X, et al.
Front Microbiol
. 2023 May;
14:1117494.
PMID: 37152732
The COVID-19 pandemic caused by SARS-CoV-2 sparked intensive research into the development of effective vaccines, 50 of which have been approved thus far, including the novel mRNA-based vaccines developed by...
3.
Ortega-Rivera O, Shin M, Moreno-Gonzalez M, Pokorski J, Steinmetz N
Adv Ther (Weinh)
. 2022 Dec;
5(10).
PMID: 36570039
The standard therapy for cardiovascular disease (CVD) is the administration of statins to reduce plasma cholesterol levels, but this requires lifelong treatment. We developed a CVD vaccine candidate that targets...
4.
Shin M, Ortega-Rivera O, Steinmetz N
Bioconjug Chem
. 2022 Oct;
33(10):1922-1933.
PMID: 36191144
Atherosclerosis is a progressive cardiovascular disease in which cholesterol-rich plaques build up within arteries, increasing the risk of thrombosis, myocardial infarction, and stroke. One promising therapeutic approach is the use...
5.
Nkanga C, Ortega-Rivera O, Shin M, Moreno-Gonzalez M, Steinmetz N
Biomacromolecules
. 2022 Mar;
23(4):1812-1825.
PMID: 35344365
Cowpea mosaic virus (CPMV) is a potent immunogenic adjuvant and epitope display platform for the development of vaccines against cancers and infectious diseases, including coronavirus disease 2019. However, the proteinaceous...
6.
Shin M, Hochberg J, Pokorski J, Steinmetz N
ACS Appl Mater Interfaces
. 2021 Dec;
13(50):59618-59632.
PMID: 34890195
Proteinaceous nanoparticles can be used to deliver large payloads of active ingredients, which is advantageous in medicine and agriculture. However, the conjugation of hydrophobic ligands to hydrophilic nanocarriers such as...
7.
Ortega-Rivera O, Shukla S, Shin M, Chen A, Beiss V, Moreno-Gonzalez M, et al.
ACS Infect Dis
. 2021 Oct;
7(11):3096-3110.
PMID: 34672530
The development of vaccines against coronaviruses has focused on the spike (S) protein, which is required for the recognition of host-cell receptors and thus elicits neutralizing antibodies. Targeting conserved epitopes...
8.
Ortega-Rivera O, Shin M, Chen A, Beiss V, Moreno-Gonzalez M, Lopez-Ramirez M, et al.
J Am Chem Soc
. 2021 Sep;
143(36):14748-14765.
PMID: 34490778
The COVID-19 pandemic highlights the need for platform technologies enabling rapid development of vaccines for emerging viral diseases. The current vaccines target the SARS-CoV-2 spike (S) protein and thus far...
9.
Hsueh H, Kim Y, Pitha I, Shin M, Berlinicke C, Chou R, et al.
Pharmaceutics
. 2021 Jun;
13(5).
PMID: 34062883
Glaucoma is the leading cause of irreversible blindness worldwide. Elevated intraocular pressure (IOP) is one of the major risk factors for glaucoma onset and progression, and available pharmaceutical interventions are...
10.
Park J, Wen A, Gao H, Shin M, Simon D, Wang Y, et al.
Biomacromolecules
. 2021 Jun;
22(6):2582-2594.
PMID: 34060817
Thromboembolic conditions are a leading cause of death worldwide, and deep vein thrombosis (DVT), or occlusive venous clot formation, is a critical and rising problem that contributes to damage of...